Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.40 |
| ▸ | MEN1 | O00255 | 6/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8597281 | 0.86 | SMN1; SMN2 (0.47) | MAPTALDH1A1LMNAL3MBTL1KMT2A | |
| SCHEMBL29179660 | 0.83 | HTT (0.45) | MAPTALDH1A1LMNAL3MBTL1KMT2A | |
| SCHEMBL8560385 | 0.83 | ALDH1A1 (0.43) | MAPTALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL4594918 | 0.81 | MAPT (0.46) | MAPTALDH1A1LMNAL3MBTL1KMT2A | |
| SCHEMBL26647446 | 0.81 | MAPT (0.46) | MAPTALDH1A1LMNAL3MBTL1KMT2A | |
| SCHEMBL21187178 | 0.79 | MAPT (0.45) | MAPTALDH1A1LMNAL3MBTL1KMT2A | |
| SCHEMBL11553810 | 0.78 | MAPT (0.57) | MAPTALDH1A1LMNAL3MBTL1KMT2A | |
| SCHEMBL8356136 | 0.78 | MAPT (0.61) | MAPTALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL24455815 | 0.78 | NOS3 (0.50) | MAPTALDH1A1LMNAL3MBTL1KMT2A | |
| SCHEMBL8567785 | 0.78 | PIN1 (0.53) | MAPTKMT2AMEN1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089592-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | BIOGEN MA INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220089592-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | BIOGEN MA INC. | 2022-03-24 | — | — | US | disclosed |
| EP-3911652-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | Biogen MA Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150626-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | BIOGEN MA INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-0453885-B1 | Process for the preparation of aromatic amines | BAYER AG (DE) | 1994-03-16 | — | — | EP | disclosed |
| US-5262539-A | Process for the preparation of aromatic amines | BAYER AKTIENGESELLSCHAFT (DE) | 1993-11-16 | — | — | US | disclosed |
| EP-0453885-A2 | Process for the preparation of aromatic amines | BAYER AG (DE) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089592-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK2, IRAK1 | MAPT 2697/4885ALDH1A1 1657/4885LMNA 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.